Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner

American Journal of Cardiology

Volumn 93, Issue 8, 2004, Pages 1046-1050

  Kajinami, Kouji ^a   Brousseau, Margaret E ^b   Ordovas, Jose M ^b   Schaefer, Ernst J ^b  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

ADULT; AGED; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOTE DETECTION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE 1 GENE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; GENES, MDR; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PYRROLES; SEX FACTORS;

EID: 1842637753     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.01.014     Document Type: Article

References (18)

1. Weinshilboum R. Inheritance and drug response. N Engl J Med. 348:2003;529-537.
2. Evans W.E., McLeod H. Pharmacogenomics. Drug disposition, drug targets, and side effects. N Engl J Med. 348:2003;538-549.
3. Kalow E., Tang B.K., Endrenyi I. Hypothesis comparison of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 8:1998;283-289.
4. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 84:1999;413-428.
5. Bogman K., Peyer A.K., Torok M., Justers E., Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol. 132:2001;1183-1192.
6. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., et al. Functional polymorphisms of the human multidrug-resistance gene multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 97:2000;3473-3478.
7. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., Taylor A., Xie H.G., McKinsey J., Zhou S., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 70:2001;189-199.
8. Fellay J., Marzolini C., Meaden E.R., Back D.J., Buclin T., Chave J.P., Decosterd L.A., Furrer H., Opravil M., Pantaleo G., et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multpidrug resistance transporter 1 a pharmacogenetics study. Lancet. 359:2002;30-36.
9. Siddiqui A., Kerb R., Weale M.E., Brinkmann U., Smith A., Goldstein D.B., Wood N.W., Sisodiya S.M. Association of multidrug resistance in epilepsy with a polymorphism in the drug transporter gene ABCB1. N Engl J Med. 348:2003;1442-1448.
10. Davidson M., McKenney J., Stein E., Schrott H.G., Fayyad R., Black D. Comparison of one year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 79:1997;1475-1481.
11. Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G., Black D.M., Stein E.M., Corella D., Ordovas J.M. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender-specific manner. Atherosclerosis. 158:2001;183-193.
12. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., Takahashi M., Kurata Y., Kigawa J., Higubhi S., et al. Expression of P-glycoprotein in human placenta relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 297:2001;1137-1143.
13. Berge K.E., von Bergmann K., Lutjohann D., Guerra R., Grundy S.M., Hobbs H.H., Cohen J.C. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG 5 and ABCG8. J Lipid Res. 43:2002;486-494.
14. Mickley L.A., Lee J.S., Weng Z., Zhan Z., Alvarez M., Wilson W., Bates S.E., Fojo T. Genetic polymorphism in MDR1 a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood. 91:1998;1749-1756.
15. Fromm M.F. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliver Rev. 54:2002;1295-1310.
16. Kurata Y., Ieiri I., Kimura M., Morita T., Irie S., Urae A., Ohdo S., Ohrani H., Sawada Y., Higuchi S., et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 72:2002;209-219.
17. Garringos M., Mir L.M., Orlowski S. Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase. Further experimental evidence for a multisite model. Eur J Biochem. 244:1997;664-673.
18. Shapiro A.B., Fox K., Lam P., Ling V. Stimulation of P-glycoprotein- mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem. 259:1999;841-850.